Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Subcutaneous Teprotumumab in Healthy Volunteers
NCT06674941Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of teprotumumab in thyroid eye disease (TED) (3 cohorts), sponsored by Amgen. Primary endpoints: Area Under the Serum Concentration-time Curve From Time 0 Extrapolated to Infinity, Area Under the Serum Concentration-time Curve From Time 0 to the Last Quantifiable Concentration and 2 more. Started Mar 2023; status: completed.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06674941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674941.